Emily Kaiser, Assistant Managing Editor

The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.

Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.

The #GlassesOn campaign promotes the benefits of eyewear for kids and invites support for the non-profit through Giving Tuesday on November 29th.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.